Furthermore, we estimated hormonal therapy for positive estrogen receptor (ER+) or positive progesterone receptor (PR+), and specific targeted therapy for positive human epidermal growth factor receptor 2 (HER2+) for breast cancer patients with or without uterine leiomyoma (Table 4). The gene discussed is ESR1; the disease is breast carcinoma.